Jordan, a country in the Middle East, has seen a rise in the prevalence of diabetes in recent years. As a result, the demand for anti-diabetes drugs has increased.
Customer preferences: Patients in Jordan prefer to use oral medications to manage their diabetes, as opposed to insulin injections. This preference is due to the ease of use and convenience of oral medications. Additionally, patients tend to choose generic medications over branded ones due to their affordability.
Trends in the market: There has been a shift towards combination therapies in Jordan, where patients are prescribed multiple medications to manage their diabetes. This trend is driven by the need for better glycemic control and to reduce the risk of side effects associated with high doses of a single medication. Additionally, there has been an increase in the use of newer classes of anti-diabetes drugs, such as GLP-1 receptor agonists and SGLT-2 inhibitors. These drugs have been shown to have better efficacy and safety profiles compared to older medications.
Local special circumstances: Jordan has a high prevalence of diabetes, with an estimated 13% of the population affected by the disease. This is due to factors such as a sedentary lifestyle, unhealthy diets, and a genetic predisposition to the disease. Additionally, the country has a high rate of obesity, which is a major risk factor for developing diabetes.
Underlying macroeconomic factors: The Jordanian government heavily subsidizes healthcare in the country, making medications more affordable for patients. However, the country has been facing economic challenges in recent years, which has led to a decrease in government spending on healthcare. This has resulted in a shift towards private healthcare, where patients have to pay out of pocket for their medications. As a result, there has been an increase in the use of generic medications, which are more affordable for patients.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
